The experimental research on the inhibiting impacts of RNAi on Cyclin E in breast cancer cell line




The aim of the study was to investigate the biological character change of breast cancer cell line by inhibiting the Cyclin E expressing level.


Human breast cancer cell line MCF-7 was transfected by Cyclin E siRNA vector pEGFP/CCNE2. SiRNA-induced silencing of Cyclin E was determined at RNA level and protein level, respectively. The proliferation of MCF-7 and its sensitivity to chemical therapy were measured by CCK-8 assay, while cell cycle was measured by flow cytometry (FCM).


The plasmid could reduce the expression of Cyclin E. The proliferation ability of MCF-7 was decreased and the sensitivity to chemical therapy was enhanced according to the inhibition of Cyclin E expression. The transfected MCF-7 was arrested at G1 phase of cell cycle.


The inhibition of Cyclin E can decrease the breast cancer cell’s growth, increase its sensation to chemical therapy and slow down its cell cycle. The Cyclin E siRNA may provide us a practical tool for further study on the gene therapy to breast cancers.

Key words

breast cancer Cyclin E RNAi 


  1. 1.
    Sutherland RL, Musgrove EA. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia, 2004, 9: 95–104.PubMedCrossRefGoogle Scholar
  2. 2.
    He WS, Huang T, Wang HJ. Expression of Cyclin E and its relationship with the prognosis of patients with breast cancer. Chinese-German J Clin Oncol, 2006, 5: 275–278.CrossRefGoogle Scholar
  3. 3.
    He WS, Huang T, Ren JH, et al. Construction and identification of Cyclin E siRNA eukaryotic expression vectors. J Med Mol Biol (Chinese), 2007, 4: 104–107.Google Scholar
  4. 4.
    Keyomarsi K, O’Leary N, Molnar G, et al. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res, 1994, 54: 380–385.PubMedGoogle Scholar
  5. 5.
    Mumberg D, Haas K, Möröy T, et al. Uncoupling of DNA replication and cell cycle progression by human cyclin E. Oncogene, 1996, 13: 2493–2497.PubMedGoogle Scholar
  6. 6.
    Cao JG, Zhou H, Peng B, et al. Reversal of multidrug resistance by neferine in adriamycin resistant human breast cancer cell line MCF-7/ADM. Chinese-German J Clin Oncol, 2004, 3: 93–96.CrossRefGoogle Scholar
  7. 7.
    Xiong HH, Yu SY, Xia S, et al. Expression of Survivin, mutant p53 and C-erbB-2 in breast cancer and its clinical significance. Chinese-German J Clin Oncol, 2005, 4: 229–231.CrossRefGoogle Scholar
  8. 8.
    Desmedt C, Ouriaghli FE, Durbecq V, et al. Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. Int J Cancer, 2006, 119: 2539–2545.PubMedCrossRefGoogle Scholar
  9. 9.
    Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med, 2002, 347: 1566–1575.PubMedCrossRefGoogle Scholar
  10. 10.
    Potemski P, Kusinska R, Watala C, et al. Cyclin E expression in breast cancer correlates with negative steroid receptor status, HER2 expression, tumor grade and proliferation. J Exp Clin Cancer Res, 2006, 25: 59–64.PubMedGoogle Scholar
  11. 11.
    Lopez-Beltran A, MacLennan GT, Montironi R. Cyclin E as molecular marker in the management of breast cancer: a review. Anal Quant Cytol Histol, 2006, 28: 111–114.PubMedGoogle Scholar
  12. 12.
    Geng Y, Yu QY, Whoriskey W, et al. Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci USA, 2001, 98: 13138–13143.PubMedCrossRefGoogle Scholar
  13. 13.
    Lents NH, Baldassare JJ. CDK2 and cyclin E knockout mice: lessons from breast cancer. Trends Endocrinol Metab, 2004, 15: 1–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Morris KV. Therapeutic potential of siRNA-mediated transcriptional gene silencing. Biotechniques, 2006, suppl: 7–13.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Thyroid and Breast Surgery, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations